Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
The trial also showed a median overall survival of 24 months compared with 14.7 months for patients receiving the best available treatment.
The trial also showed a median overall survival of 24 months compared with 14.7 months for patients receiving the best available treatment.